Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice-Reference-Cited by-同舟云学术

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

Published:2020-10-06 Issue:1 Volume:62 Page:194-202
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Zackova Daniela¹,Klamova Hana²,Belohlavkova Petra³,Stejskal Lukas⁴,Necasova Tereza⁵,Semerad Lukas¹,Weinbergerova Barbora¹,Srbova Dana²,Voglova Jaroslava³,Cicatkova Petra¹,Sustkova Zuzana¹,Hornak Tomas¹,Baranova Jana⁵,Prochazkova Jirina¹,Mayer Jiri¹⁶

Affiliation:

1. Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic

2. Institute of Hematology and Blood Transfusion, Praha, Czech Republic

3. 4th Department of Internal Medicine – Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic

4. Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic

5. Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic

6. Central European Institute of Technology, Brno, Czech Republic

Funder

Masarykova Univerzita

The Czech Leukemia Study Group for life – CELL

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1827242

Reference38 articles.

1. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

2. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

3. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

4. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value

5. Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of Small Molecule Anticancer NF-κB Inhibitors;Creative surgery and oncology;2023-06-30

2. Dasatinib;Reactions Weekly;2021-03